Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses: 2018-2025

Historic Other Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 7 years, with Sep 2025 value amounting to $1.7 million.

  • Agios Pharmaceuticals' Other Operating Expenses fell 99.16% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 97.18%. This contributed to the annual value of $200.0 million for FY2024, which is 6842.03% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Other Operating Expenses of $1.7 million as of Q3 2025, which was down 1.35% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Other Operating Expenses ranged from a high of $200.0 million in Q3 2024 and a low of -$9.9 million during Q4 2022.
  • Over the past 3 years, Agios Pharmaceuticals' median Other Operating Expenses value was $1.1 million (recorded in 2023), while the average stood at $19.2 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Other Operating Expenses crashed by 475.14% in 2022 and then surged by 31,495.58% in 2024.
  • Agios Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $2.6 million in 2021, then slumped by 475.14% to -$9.9 million in 2022, then skyrocketed by 105.92% to $586,000 in 2023, then spiked by 115.02% to $1.3 million in 2024, then tumbled by 99.16% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.7 million for Q2 2025, and $1.1 million during Q1 2025.